Elicit
AI NativeElicit helps researchers be 10x more evidence-based
Est 2023|Valuation $100M|Raised $33M
Elicit helps researchers be 10x more evidence-based
Published Sep 16, 2026
The vendor has published product announcements through 2025 describing feature additions (e.g., Research Agents, keyword search in systematic reviews, clinical trials support, alerts). Specific future delivery dates and guarantees are not consistently provided in public materials.
The G2 listing for Elicit shows limited review volume for the product identity observed; some entries suggest potential listing confusion with adjacent products. Visible reviews include both praise and criticism regarding summarization quality and workflow limitations.
Interpretation: historical workflow friction around saving/exporting/modifying searches was reported by reviewers.
Capterra shows a very small number of reviews with mixed observations: a graduate student reviewer reported the product is easy to use and provides reasonable summaries, while noting the output format can be visually large and space-consuming. Platform sub-scores derived from limited reviews are not statistically meaningful.
Community threads show a range of opinions and recurring concerns:
Common motivators include:
Deal-breakers suggested by reviews and community discussion include:
The vendor has published evaluation notes describing studies with professional researchers and describes evaluator backgrounds and protocols. These vendor-run evaluations are directional but should be supplemented with independent testing during procurement or pilot projects.
Get a comprehensive analysis of Elicit including market position, competitive landscape, adoption trends, and peer benchmarks.
Download full report →If comprehensive coverage of grey literature (industry reports, policy briefs, internal PDFs at scale) is the primary requirement. The product is oriented to academic literature and clinical trials, and complementary tools may be required for extensive grey literature ingestion.
If the organization cannot accommodate a verification step. If stakeholders expect AI outputs to be publish-ready without human review, this family of tools (including this product) is unlikely to meet that expectation.
If the field is mainly paywalled and institutional access is not available. Community comments indicate limited utility in those circumstances.
If the primary need is a research-writing suite rather than structured evidence extraction. Other tools may be better aligned when manuscript drafting and citation generation are the central workflows.
If procurement requires extensive third-party validation and publicly visible review volume. Public review volumes for this vendor in major review platforms were limited in the sources reviewed.
Vendor materials describe case examples such as:
Critical evaluation: these case study metrics are vendor-published. Methodological details (sampling, definitions of correctness, QA procedures, exclusion criteria) are not fully transparent in marketing snippets; procurement teams should request detailed methodology, raw evaluation data, and inter-rater reliability metrics before using such figures as a procurement justification.
Elicit is an AI research assistant focused on scientific and academic evidence work. Typical capabilities described by the vendor and observable in documentation include:
The product is positioned to emphasize tables, workflows, traceable citations/quotes, and the ability to process multiple papers concurrently.
Elicit is positioned for:
It operates in the emerging category of AI-assisted literature discovery and evidence synthesis, functioning between traditional scholarly search engines (PubMed/Google Scholar) and general-purpose large language model tools.